Menu
Search
|

Menu

Close
X

Progenics Pharmaceuticals Inc PGNX.OQ (NASDAQ Stock Exchange Global Select Market)

8.36 USD
-- (--)
As of Jul 16
chart
Previous Close 8.36
Open --
Volume --
3m Avg Volume 338,025
Today’s High --
Today’s Low --
52 Week High 9.11
52 Week Low 4.61
Shares Outstanding (mil) 73.72
Market Capitalization (mil) 613.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
12
FY16
69
FY15
9
EPS (USD)
FY18
-0.185
FY17
-0.779
FY16
0.152
FY15
-0.561
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
48.91
8.04
Price to Book (MRQ)
vs sector
10.04
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
82.07
17.43
LT Debt to Equity (MRQ)
vs sector
74.26
13.25
Return on Investment (TTM)
vs sector
-35.11
13.23
Return on Equity (TTM)
vs sector
-69.09
15.27

EXECUTIVE LEADERSHIP

Peter Crowley
Independent Chairman of the Board, Since 2010
Salary: --
Bonus: --
Mark Baker
Chief Executive Officer, Director, Since 2011
Salary: $614,325.00
Bonus: --
Patrick Fabbio
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $375,291.00
Bonus: --
Vivien Wong
Executive Vice President - Development, Since 2016
Salary: $407,459.00
Bonus: --
Benedict Osorio
Senior Vice President - Quality, Since 2018
Salary: $306,634.00
Bonus: $114,988.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 World Trade Ctr Fl 47
NEW YORK   NY   10007-0089

Phone: +1646.9752500

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

SPONSORED STORIES